Atkinson Edward Morrow III

Insider profile

Atkinson Edward Morrow III's trades of Vertex Pharmaceuticals Incorporated's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
US 89Bio Inc (ETNB)
Transaction date
Planned sale
Price
17.91
Quantity 6,250 -100.0%
Value US$111,938
US 89Bio Inc (ETNB)
Transaction date
Proposed sale
Price
17.91
Quantity 6,250
Value US$111,961
US 89Bio Inc (ETNB)
Transaction date
Planned sale
Price
13.60
Quantity 10,000 -100.0%
Value US$136,000
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-02-26 2026-02-25
PlS Planned sale
60,094 +12.5%
493.20
US$2,359,035 		60,094 +12.5% 493.20 US$2,359,035
2026-02-25 2026-02-25
PrS Proposed sale
1,155
78.71
US$3,863,567 		1,155 78.71 US$3,863,567
2026-02-19 2026-02-18
PlS Planned sale
33,309 +15.9%
24.17
US$2,523,367 		33,309 +15.9% 24.17 US$2,523,367
2026-02-18 2026-02-18
PrS Proposed sale
817
473.68
US$386,997 		817 473.68 US$386,997
2026-02-19 2026-02-17
PlS Planned sale
2,031 -8.6%
489.46
US$994,093 		2,031 -8.6% 489.46 US$994,093
2026-02-17 2026-02-17
PrS Proposed sale
2,031
489.46
US$994,093 		2,031 489.46 US$994,093
2026-02-12 2026-02-11
PlS Planned sale
1,751 -7.4%
460.43
US$806,213 		1,751 -7.4% 460.43 US$806,213
2026-02-11 2026-02-11
PrS Proposed sale
1,751
460.43
US$806,213 		1,751 460.43 US$806,213
2025-11-19 2025-11-17
PlS Planned sale
2,500 -12.9%
434.58
US$1,086,450 		2,500 -12.9% 434.58 US$1,086,450
2025-11-17 2025-11-17
PrS Proposed sale
2,500
434.58
US$1,086,450 		2,500 434.58 US$1,086,450
2025-02-28 2025-02-27
PlS Planned sale
2,650 -12.0%
475.34
US$1,259,651 		2,650 -12.0% 475.34 US$1,259,651
2025-02-27 2025-02-27
PrS Proposed sale
2,650
475.34
US$1,259,651 		2,650 475.34 US$1,259,651
2025-02-26 2025-02-25
PlS Planned sale
1,767 -6.7%
480.95
US$849,839 		1,767 -6.7% 480.95 US$849,839
2025-02-25 2025-02-25
PrS Proposed sale
1,767
480.95
US$849,839 		1,767 480.95 US$849,839
2025-02-12 2025-02-11
PlS Planned sale
1,747 -7.0%
459.83
US$803,323 		1,747 -7.0% 459.83 US$803,323
2025-02-11 2025-02-11
PrS Proposed sale
1,747
459.83
US$803,323 		1,747 459.83 US$803,323
2024-06-13 2024-06-12
PlS Planned sale
7,288 -31.3%
478.00
US$3,483,664 		7,288 -31.3% 478.00 US$3,483,664
2024-06-12 2024-06-12
PrS Proposed sale
7,288
478.00
US$3,483,664 		7,288 478.00 US$3,483,664
2024-02-27 2024-02-26
PlS Planned sale
883 -5.2%
425.70
US$375,893 		883 -5.2% 425.70 US$375,893
2024-02-26 2024-02-26
PrS Proposed sale
883
425.70
US$375,893 		883 425.70 US$375,893
2024-02-23 2024-02-21
PlS Planned sale
1,201 -6.1%
421.77
US$506,546 		1,201 -6.1% 421.77 US$506,546
2024-02-21 2024-02-21
PrS Proposed sale
1,201
421.77
US$506,546 		1,201 421.77 US$506,546
2024-02-21 2024-02-20
PlS Planned sale
801 -3.9%
420.79
US$337,053 		801 -3.9% 420.79 US$337,053
2024-02-20 2024-02-20
PrS Proposed sale
801
420.79
US$337,053 		801 420.79 US$337,053
2024-02-13 2024-02-12
PlS Planned sale
913 -3.8%
420.24
US$383,679 		913 -3.8% 420.24 US$383,679
2024-02-12 2024-02-12
PrS Proposed sale
913
420.24
US$383,679 		913 420.24 US$383,679
2023-06-05 2023-06-01
US 89Bio Inc (ETNB)
PlS Planned sale
6,250 -100.0%
17.91
US$111,938 		6,250 -100.0% 17.91 US$111,938
2023-06-01 2023-06-01
US 89Bio Inc (ETNB)
PrS Proposed sale
6,250
17.91
US$111,961 		6,250 17.91 US$111,961
2023-03-03 2023-03-01
US 89Bio Inc (ETNB)
PlS Planned sale
10,000 -100.0%
13.60
US$136,000 		10,000 -100.0% 13.60 US$136,000